Our Pricing

Wegovy Weight Loss Injections UK: Clinical Evidence and Pricing

Published on: June 03, 2026

Searching for transparent wegovy weight loss injections uk price information? At Cured Pharmacy, Wegovy starts from £79.00 with upfront pricing, a free clinical consultation completed in under 3 minutes, and genuine UK-licensed medication dispensed by our GPhC-registered team. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets MHRA standards for safety and efficacy.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone, which regulates appetite by acting on brain regions that control hunger and satiety, whilst also slowing gastric emptying to promote feelings of fullness.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most significant weight loss outcomes demonstrated in pharmaceutical trials for obesity treatment. The once-weekly subcutaneous injection offers a convenient dosing schedule that supports long-term adherence, a critical factor in sustained weight management.

Wegovy Dosing Schedule and Treatment Timeline

Gradual Dose Escalation Protocol

Wegovy follows a structured 16-week dose escalation designed to minimise gastrointestinal side effects whilst optimising therapeutic response [2]. Treatment begins at 0.25 mg weekly for four weeks, then increases monthly through 0.5 mg, 1 mg, and 1.7 mg, before reaching the maintenance dose of 2.4 mg weekly. This gradual titration allows your body to adapt to the medication's effects on appetite and digestion.

Your UK prescriber may adjust this schedule based on your individual tolerance and clinical response. Some patients remain on a lower maintenance dose if they achieve their weight loss goals or experience persistent side effects at higher doses. All dosing decisions require ongoing clinical assessment to ensure treatment remains safe and appropriate for your circumstances.

Clinical Evidence: STEP Trial Programme Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme enrolled over 4,500 participants across five major studies, establishing the robust evidence base for Wegovy's efficacy [1][2]. STEP 1 demonstrated that 86.4% of participants achieved at least 5% weight loss, whilst 69.1% achieved 10% or greater reduction — outcomes that exceed most lifestyle interventions and earlier pharmacological treatments.

STEP 3 combined semaglutide with intensive behavioural therapy, resulting in an average 16% body weight reduction [3]. This finding underscores that Wegovy works most effectively when integrated with dietary modifications and increased physical activity. The trials also revealed improvements in cardiometabolic markers, including reductions in waist circumference, blood pressure, and HbA1c levels in participants with prediabetes.

Long-term data from STEP 4 showed that participants who discontinued Wegovy after 20 weeks regained approximately two-thirds of their lost weight within 48 weeks, whilst those continuing treatment maintained their weight loss [3]. This evidence suggests that obesity requires ongoing pharmacological management for sustained results, similar to other chronic conditions like hypertension or diabetes.

Wegovy Weight Loss Injections UK Price Comparison

Transparent Pricing at Cured Pharmacy

At Cured Pharmacy, Wegovy starts from £79.00, representing the lowest guaranteed pricing in the UK market. Unlike some providers who display prices only after consultation, we believe in complete transparency — you'll see the exact cost before beginning your clinical assessment. This upfront approach allows you to make informed decisions about your weight management investment.

Our pricing includes the medication, UK prescriber consultation, and discreet delivery to your chosen address. There are no hidden fees or subscription traps. The final cost depends on your prescribed dose and treatment duration, which your UK-registered clinician determines based on your medical history, current medications, and weight loss goals. All Wegovy supplied by Cured Pharmacy is genuine UK-licensed medication sourced through regulated pharmaceutical supply chains.

Common Side Effects and Management Strategies

The most frequently reported side effects of Wegovy are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [2]. These effects typically emerge during dose escalation and often diminish as your body adapts to the medication. In clinical trials, nausea affected approximately 44% of participants, though most cases were mild to moderate in severity.

To minimise digestive symptoms, eat smaller portions, avoid high-fat meals, and stay well-hydrated throughout treatment. Some patients find that taking Wegovy on the same day each week after a light meal reduces nausea. If side effects persist or become severe, contact your prescriber — they may recommend slowing the dose escalation or temporarily reducing your dose. Serious adverse events are rare but include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications.

Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [2]. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your clinical assessment will screen for these contraindications before prescribing.

Who Can Use Wegovy: Eligibility and Contraindications

Clinical Assessment Requirements

Wegovy is licensed for adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. Your UK prescriber will calculate your BMI and review your medical history during the online consultation to confirm eligibility. Treatment is not appropriate for cosmetic weight loss in individuals with a healthy BMI.

Wegovy is contraindicated in pregnancy, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation. The medication is also unsuitable for patients with a history of severe gastrointestinal disease, including inflammatory bowel disease or gastroparesis. Your prescriber will assess for drug interactions, particularly with medications that affect blood sugar levels or gastrointestinal motility. All prescription decisions are made by UK-registered clinicians following MHRA guidance and NICE recommendations.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.